New drug cocktail shows promise in preventing bile duct cancer return after surgery
NCT ID NCT05254847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (capecitabine, lenvatinib, and tislelizumab) given after surgery to 65 adults with biliary tract cancer. The goal was to see if this treatment could help keep the cancer from coming back. The results focus on how long patients lived without the cancer returning and any side effects they experienced.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers